Retatrutide Prescribed Online to Connecticut Residents

Medical Weight Loss Treatment in Connecticut

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Connecticut

From the corporate corridors of Stamford to the historic streets of New Haven, Connecticut residents lead busy lives that demand flexible healthcare. OmniRx Health serves the entire Constitution State—whether you're commuting to NYC for work, studying at Yale, or enjoying retirement along the Connecticut shoreline. Our telehealth services bring expert medical care directly to you, saving precious time in one of America's most fast-paced regions.

OmniRx Health providers are licensed by the Connecticut Medical Examining Board to deliver telehealth throughout the state.

Partner pharmacies across Hartford, New Haven, Stamford, and throughout Connecticut ensure quick prescription fulfillment and delivery.

Connecticut requires insurers to cover telehealth services and has expanded virtual care access with permanent legislation supporting remote healthcare delivery.

Connecticut mandates insurance coverage for telehealth at parity with in-person visits, making virtual care accessible and affordable for most residents.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Connecticut?: Yes, Connecticut has robust telehealth laws that fully support virtual healthcare. Licensed providers can offer consultations, diagnose conditions, and prescribe medications through secure video platforms.
Can Connecticut residents get prescriptions via telehealth?: Yes, Connecticut allows telehealth providers to prescribe medications following a proper virtual evaluation. Prescriptions are sent to your preferred local pharmacy or can be delivered to your home.
Does Connecticut insurance cover telehealth visits?: Connecticut law requires health insurers to cover telehealth services at the same rate as in-person appointments. Most commercial plans, as well as HUSKY Health (Medicaid), cover virtual visits.